US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Silexion Therapeutics Corp

1.04

-0.0596-5.42%

Volume:112.53K

Turnover:119.22K

Market Cap:8.75M

PE:-0.86

High:1.11

Open:1.08

Low:1.03

Close:1.10

Loading ...

Overview Company News Filings

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

Silexion Therapeutics, Evonik collaborate on siRNA formulation development

Silexion Therapeutics Collaborates With Evonik on Advanced Sirna Formulation Development

THOMSON REUTERS

Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development

Silexion Therapeutics appoints Peled to board of directors

Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors

THOMSON REUTERS

Press Release: Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors

Agilent, Bath & Body Works And 3 Stocks To Watch Heading Into Monday

Silexion Therapeutics announces 1-for-9 reverse share split

BRIEF-Silexion Therapeutics Announces 1-For-9 Reverse Share Split

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

THOMSON REUTERS

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

Silexion Therapeutics Corp Qtrly EPS $-2.03

THOMSON REUTERS

Silexion Therapeutics initiated with a Buy at Maxim

Silexion Therapeutics Corp : Maxim Group Initiates Coverage With Buy Rating; Target Price $1

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SLXN/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLXN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":1.0404,"timestamp":1743534542194,"preClose":1.1,"halted":0,"volume":112525,"delay":0,"floatShares":5231700,"shares":8414615,"eps":-1.215216,"marketStatus":"Trading","change":-0.0596,"latestTime":"04-01 15:11:01 EDT","open":1.08,"high":1.105,"low":1.03,"amount":119223.79328999999,"amplitude":0.068182,"askPrice":1.05,"askSize":300,"bidPrice":1.03,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-1.215216,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743537600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":1.1,"preHourTrading":{"tag":"盘前","latestPrice":1.08,"preClose":1.1,"latestTime":"09:22 EDT","volume":6825,"amount":7246.3393275,"timestamp":1743513736347},"postHourTrading":{"tag":"盘后","latestPrice":1.06,"preClose":1.1,"latestTime":"19:58 EDT","volume":14020,"amount":15038.3478,"timestamp":1743465507604},"volumeRatio":0.600814},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","floatShares":5231700,"roa":"--","roe":"--","lyrEps":0.386244,"volumeRatio":0.600814,"shares":8414615,"dividePrice":0,"high":1.105,"amplitude":0.068182,"preClose":1.1,"low":1.03,"week52Low":0.575,"pbRate":"--","week52High":122.0184,"institutionHeld":0,"latestPrice":1.0404,"committee":-0.2,"eps":-1.215216,"divideRate":0,"volume":112525,"delay":0,"ttmEps":-1.215216,"open":1.08,"prevYearClose":2.01,"prevWeekClose":1.17,"prevMonthClose":1.1,"prevQuarterClose":1.1,"fiveDayClose":1.19,"twentyDayClose":1.11,"sixtyDayClose":1.99},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLXN\",pageSize:16,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2492167965","title":"PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2492167965","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492167965?lang=en_us&edition=fundamental","pubTime":"2024-12-17 22:36","pubTimestamp":1734446160,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics  is advancing precision oncology with a focus on KRAS-driven cancers, among the most challenging targets in oncology. In collaboration with Evonik, Silexion has developed a long-acting PLGA microparticle formulation for SIL-204, its next-generation siRNA candidate. Preclinical studies showed high efficacy, with sustained-release therapy effectively reducing tumor size in KRAS-mutated pancreatic cancer models.Silexion’s RNAi approach silences KRAS mutations at the genetic level, overcoming barriers that limit small-molecule inhibitors. This advancement comes as the oncology industry sees surging M&A activity, such as Pfizer’s $43 billion acquisition of Seagen and AbbVie’s $10.1 billion purchase of Immunogen, reflecting Big Pharma’s demand for innovative cancer therapies.Silexion has taken a differentiated approach, utilizing RNAi to silence KRAS mutations at the genetic level. Its Local Drug EluteR  platform bypasses the tumor microenvironment’s barriers, deliverin","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/a28AzTi8fHvfur5v_XpklQ--~B/aD0yMzU7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/9f1becdf8f481d7dc7b8c6cea3e6067b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/a28AzTi8fHvfur5v_XpklQ--~B/aD0yMzU7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/9f1becdf8f481d7dc7b8c6cea3e6067b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pesg-releases-market-silexion-therapeutics-143600317.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1066053197.SGD","LENZ","SG9999001176.USD","LU1066051498.USD","LU0170899867.USD","IE000M9KFDE8.USD","IE00BBT3K403.USD","LU0868494617.USD","IE00B19Z3581.USD","BK4599","LU0058720904.USD","SG9999002232.USD","BK4007","LU0122379950.USD","BK4534","LU0289739699.SGD","SG9999003800.SGD","LU1023059063.AUD","LU1894683348.USD","BK4585","BK4588","BK4568","BK4581","IE0002270589.USD","BK4550","LU0225771236.USD","BK4592","SLXNW","BK4533","SG9999001176.SGD","PFE","LU1883839398.USD","LU1894683264.USD","SLXN","LU0234572021.USD","LU0306807586.USD","LU0225284248.USD","IE00B19Z3B42.SGD","SGXZ57979304.SGD","BK4139","IE00BLSP4452.SGD","LU0306806265.USD","IE00BLSP4239.USD","LU0321505439.SGD","SG9999002224.SGD","SG9999011175.SGD","LU0321505868.SGD","LU0985481810.HKD","LU0456855351.SGD"],"gpt_icon":1},{"id":"2492958543","title":"Silexion Therapeutics, Evonik collaborate on siRNA formulation development","url":"https://stock-news.laohu8.com/highlight/detail?id=2492958543","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492958543?lang=en_us&edition=fundamental","pubTime":"2024-12-17 19:35","pubTimestamp":1734435318,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics (SLXN) revealed its ongoing collaboration with Evonik for the development of an advanced siRNA formulation aimed at enhancing...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-evonik-collaborate-on-sirna-formulation-development?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-evonik-collaborate-on-sirna-formulation-development?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","SLXN","BK4139"],"gpt_icon":0},{"id":"2492930765","title":"Silexion Therapeutics Collaborates With Evonik on Advanced Sirna Formulation Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2492930765","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492930765?lang=en_us&edition=fundamental","pubTime":"2024-12-17 19:30","pubTimestamp":1734435000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUA4DT1JT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2492598829","title":"Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2492598829","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492598829?lang=en_us&edition=fundamental","pubTime":"2024-12-17 19:30","pubTimestamp":1734435000,"startTime":"0","endTime":"0","summary":"Silexion is collaborating with Evonik on the development of a long-acting siRNA PLGA microparticle formulation, which has demonstrated high efficacy in preclinical models for KRAS-mutated cancersCayma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/17/2998086/0/en/Silexion-Therapeutics-collaborates-with-Evonik-on-advanced-siRNA-Formulation-Development.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","LENZ","BK4139"],"gpt_icon":0},{"id":"2490015989","title":"Silexion Therapeutics appoints Peled to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2490015989","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490015989?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:46","pubTimestamp":1733838361,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics (SLXN) announced the appointment of Prof. Amnon Peled as an independent director to its Board of Directors. Published first o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-appoints-peled-to-board-of-directors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-appoints-peled-to-board-of-directors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLXN","LENZ","BK4139"],"gpt_icon":0},{"id":"2490013332","title":"Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2490013332","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490013332?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:30","pubTimestamp":1733837401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUA4253MQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2490533013","title":"Press Release: Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2490533013","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490533013?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:30","pubTimestamp":1733837400,"startTime":"0","endTime":"0","summary":"Prof. Peled, a globally recognized scientific authority who has been involved in multiple successful publicly traded bio-pharma companies, will assist Silexion as it advances its RNAi platform and next-generation therapies targeting KRAS mutations. Ilan Hadar, Chairman and CEO of Silexion, commented: \"We are thrilled to welcome Prof. Peled to our Board of Directors. His unparalleled expertise in cancer biology, stem cell mobilization, and therapeutic development will be invaluable as Silexion continues to advance its pipeline of RNAi-based therapies for difficult-to-treat cancers. Prof. Peled's track record in translating innovative science into impactful clinical outcomes aligns perfectly with our mission to address unmet needs in oncology.\". Prof. Peled serves as the Director of the Gene Therapy Institute at Hadassah Medical Center in Jerusalem, where his research focuses on cytokine roles in hematopoietic stem cell biology, inflammation, and cancer. Over his 28-year career, he has l","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","SLXN","BK4585","BK4139","BK4555","TQQQ","PSQ",".IXIC","NQmain","BK4588","LENZ","QLD","BLRX","QID","SQQQ","03160","MNQmain","TM"],"gpt_icon":1},{"id":"2486798776","title":"Agilent, Bath & Body Works And 3 Stocks To Watch Heading Into Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2486798776","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486798776?lang=en_us&edition=fundamental","pubTime":"2024-11-25 15:37","pubTimestamp":1732520261,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/42157427/agilent-bath-body-works-and-3-stocks-to-watch-heading-into-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2413666426.HKD","NQmain","BK4554","LU2092937221.SGD","09439","BK4601","MNQmain","LU1165135440.EUR","BK4187","SLXN","BK1611","BK4585","09008","09042","BBWI","BK4567","PSQ","BK4121","BK4505","QID","LU1861558580.USD","A","BK4200","LU2041044095.USD","SQQQ","BK4139","BK4532","QLD","BK4548","WWD","BK4588","LU1543694498.USD","LU0347712357.USD","BK4525",".IXIC","BK4594","LU1721428933.USD","03439","LU1861559042.SGD","BK4551","LU2413666699.HKD","83042","ZM","BK4535","BK4528","03008","03042","TQQQ"],"gpt_icon":1},{"id":"2485821271","title":"Silexion Therapeutics announces 1-for-9 reverse share split","url":"https://stock-news.laohu8.com/highlight/detail?id=2485821271","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485821271?lang=en_us&edition=fundamental","pubTime":"2024-11-23 05:39","pubTimestamp":1732311557,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics  has announced a 1-for-9 reverse share split of its ordinary shares.The reverse share split will become effective after market close on November 27, 2024, and the company’s ordinary shares will begin trading on a split-adjusted basis on the Nasdaq Global Market at market open on November 29, 2024.The reverse share split is intended to enable SLXN to regain and maintain compliance with Nasdaq’s minimum bid price requirement.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4323504-silexion-therapeuticsannounces-1-for-9-reversesharesplit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["QID",".IXIC","MNQmain","TQQQ","NQmain","PSQ","LENZ","SLXN","SQQQ","QLD","BK4139"],"gpt_icon":1},{"id":"2485020214","title":"BRIEF-Silexion Therapeutics Announces 1-For-9 Reverse Share Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2485020214","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485020214?lang=en_us&edition=fundamental","pubTime":"2024-11-23 05:31","pubTimestamp":1732311063,"startTime":"0","endTime":"0","summary":"BRIEF-Silexion Therapeutics Announces 1-For-9 Reverse Share SplitNov 22 (Reuters) - Silexion Therapeutics Corp SLXN.O:SILEXION THERAPEUTICS ANNOUNCES 1-FOR-9 REVERSE SHARE SPLITSource text: ID:nGNX3tpmPfFurther company coverage: SLXN.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nTUA5VC4Y7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2485214019","title":"Silexion Therapeutics Announces 1-for-9 Reverse Share Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2485214019","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485214019?lang=en_us&edition=fundamental","pubTime":"2024-11-23 05:30","pubTimestamp":1732311000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nTUA5VC4Y7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2485212504","title":"Silexion Therapeutics Announces 1-for-9 Reverse Share Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2485212504","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485212504?lang=en_us&edition=fundamental","pubTime":"2024-11-23 05:30","pubTimestamp":1732311000,"startTime":"0","endTime":"0","summary":"Trading on split-adjusted basis will begin at market open on November 29, 2024. This adjustment is expected to help Silexion comply with NASDAQ requirements, enhance its market position, and support i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/22/2986213/0/en/Silexion-Therapeutics-Announces-1-for-9-Reverse-Share-Split.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","BK4139","QLD","MNQmain",".IXIC","QID","SLXN","TQQQ","PSQ","SQQQ","LENZ"],"gpt_icon":1},{"id":"2484116299","title":"Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2484116299","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484116299?lang=en_us&edition=fundamental","pubTime":"2024-11-20 21:30","pubTimestamp":1732109400,"startTime":"0","endTime":"0","summary":"GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp.  , a clinical-stage biotech developing RNA interference  therapies for KRAS-driven cancers, today announced that the Company’s management will be attending and presenting at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference taking place December 3-4, 2024, in Boca Raton, Florida.Ilan Hadar, Chief Executive Officer will deliver a company presentation titled “Transforming Cancer Care: Silexion Therapeutics’ Innovative Approach to Pancreatic Cancer” on December 4, 2024 at 11:30 am. A replay of the presentation will be posted, when available, to Silexion’s website on the Presentation & Events page of the investors section.The Company’s management team will be available for one-on-one meetings throughout the summit. Interested investors are encouraged to contact the Noble investor outreach team to schedule a meeting.Company ContactSilexion Therapeutics CorpMs. Mirit Horenshtein Hadar, CFOmirit@silexion.com. Inve","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Un.hGXlTo1cWDf6G_r8gjg--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/b1e94b4510f2ad8788ae48a718a249db","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Un.hGXlTo1cWDf6G_r8gjg--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/b1e94b4510f2ad8788ae48a718a249db"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/silexion-therapeutics-present-noble-capital-133000505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4139","EQR","BK4215","NBL","SLXNW","SLXN","BK4585","BK4588"],"gpt_icon":1},{"id":"2483809078","title":"Silexion Therapeutics Corp Qtrly EPS $-2.03","url":"https://stock-news.laohu8.com/highlight/detail?id=2483809078","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483809078?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:32","pubTimestamp":1731594734,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nFWN3ML0OV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2480001379","title":"Silexion Therapeutics initiated with a Buy at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2480001379","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480001379?lang=en_us&edition=fundamental","pubTime":"2024-11-01 19:31","pubTimestamp":1730460710,"startTime":"0","endTime":"0","summary":"Maxim initiated coverage of Silexion Therapeutics (SLXN) with a Buy rating and $1 price target Published first on TheFly – the ultimate source for ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-initiated-with-a-buy-at-maxim?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-initiated-with-a-buy-at-maxim?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SLXN","LENZ"],"gpt_icon":0},{"id":"2480009125","title":"Silexion Therapeutics Corp : Maxim Group Initiates Coverage With Buy Rating; Target Price  $1","url":"https://stock-news.laohu8.com/highlight/detail?id=2480009125","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480009125?lang=en_us&edition=fundamental","pubTime":"2024-11-01 19:24","pubTimestamp":1730460273,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241101:nFWN3M8056:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"gpt_icon":0}],"pageSize":16,"totalPage":5,"pageCount":4,"totalSize":70}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLXN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-29","symbol":"SLXN","defaultRemindTime":1732890600000,"type":"split","dateTimestamp":1732856400000,"forFactor":9,"toFactor":1,"ratio":9},{"market":"US","date":"2024-08-13","symbol":"SLXN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLXN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLXN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1730692800000}}}